Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Optiscan Imaging Ltd is engaged in development and commercialization of confocal microscopes for clinical and pre-clinical applications. The company develops its own InVivage device for clinical use in the oral cancer and other cancer applications; commencement of seeking regulatory approval to market the InVivage device in the United States for clinical use in oral cancer screening and surgery; continuation of its collaboration with Carl Zeiss Meditech; Marketing of the FIVE2 (ViewnVivo) system in pre-clinical and translational research markets; progressing clinical studies with researchers and medical institutions; and continuing development of new pre-clinical applications for Optiscan's products and services.
|03 Dec 2021||$0.19||$0.00||0.00%||19,646||$0.19||$0.19||$0.19|
|02 Dec 2021||$0.19||$-0.01||-5.26%||61,623||$0.20||$0.20||$0.19|
|01 Dec 2021||$0.19||$0.01||5.41%||37,677||$0.19||$0.19||$0.19|
|30 Nov 2021||$0.19||$0.01||5.56%||30,178||$0.18||$0.19||$0.18|
|29 Nov 2021||$0.18||$-0.02||-10.00%||176,684||$0.18||$0.18||$0.18|
|26 Nov 2021||$0.20||$0.01||5.13%||814,836||$0.20||$0.20||$0.15|
|25 Nov 2021||$0.20||$0.00||0.00%||46,809||$0.20||$0.20||$0.20|
|24 Nov 2021||$0.20||$-0.01||-5.00%||92,690||$0.20||$0.20||$0.20|
|23 Nov 2021||$0.20||$0.00||0.00%||186,804||$0.21||$0.21||$0.20|
|22 Nov 2021||$0.20||$0.00||0.00%||56,935||$0.20||$0.20||$0.20|
|19 Nov 2021||$0.20||$-0.02||-9.09%||310,240||$0.21||$0.21||$0.19|
|18 Nov 2021||$0.22||$0.01||4.76%||80,000||$0.22||$0.22||$0.22|
|17 Nov 2021||$0.21||$0.00||0.00%||8,146||$0.22||$0.22||$0.21|
|16 Nov 2021||$0.21||$0.01||4.88%||82,010||$0.22||$0.22||$0.21|
|15 Nov 2021||$0.21||$-0.01||-4.76%||173,359||$0.22||$0.22||$0.21|
|12 Nov 2021||$0.21||$-0.01||-4.55%||232,070||$0.23||$0.23||$0.21|
|11 Nov 2021||$0.22||$0.02||10.00%||148,743||$0.21||$0.22||$0.21|
|10 Nov 2021||$0.20||$-0.02||-9.09%||382,299||$0.22||$0.23||$0.20|
|09 Nov 2021||$0.22||$0.02||9.76%||216,420||$0.21||$0.22||$0.21|
|08 Nov 2021||$0.21||$-0.01||-4.65%||140,116||$0.21||$0.21||$0.21|
|09 Aug 2021||Karen Borg||Issued||1||$230,000||
Issue of options.
|06 May 2021||Robert Cooke||Issued||2||$780,000||
Issue of options.
|01 Apr 2021||Darren Lurie||Buy||7||$410,000||
Exercise of options.
|01 Apr 2021||Darren Lurie||Exercise||7||$410,000||
Exercise of options.
|01 Apr 2021||Philip Currie||Exercise||4||$294,000||
Exercise of options.
|01 Apr 2021||Philip Currie||Buy||4||$294,000||
Exercise of options.
|Mr Ronnie (Ron) Song||Non-Executive Director||Feb 2021||
Mr Song has had a 25-year business career in Australia before being headhunted in 1999 to assist in expanding a European motor vehicle franchise in Singapore. Ron was appointed Managing Director and Partner of V-TEC Asia Pte Ltd between February 2011 and 2013. He was also appointed Executive Director of the Pine Millennium Capital Pte Ltd during May 2014 - December 2017.
|Mr Robert Cooke||Non-Executive ChairmanNon-Executive Director||Apr 2021||
Mr Cooke is the former Managing Director & CEO of Healthscope. He is currently a non-executive director of Icon Group and Evercare Group. With a 40-plus year career in the health industry, his experience spans to executive leadership of publicity listed and privately owned healthcare companies, and a management of private and public hospitals in Australia, Asian and the UK.
|Mr Darren Lurie||Executive DirectorManaging Director||Apr 2018||
Mr Lurie is an experienced leader of boards and management teams as Chair, CEO and CFO. He has experience working across a range of industries operating both domestically and internationally. Prior to joining Optiscan, Darren was the Group CFO and Head of Corporate Development for EduCo International Group. Darren is a former chair and non-executive director of ASX listed Farm Pride Foods Ltd. He has fifteen years' experience as a corporate advisor leading finance, strategy and merger and acquisition assignments across a range of industries.
|Dr Philip James Currie||Non-Executive Director||Jul 2017||
Dr Currie has more than 36 years of experience in cardiology both in the United States and in Australia with experience in medical research, clinical cardiology and business.
|Ms Karen Borg||Non-Executive Director||Jul 2021||
Ms Borg is a senior private and public sector leader, with experience in medical devices and technology, consumer products and government services. Karen has held senior roles in international and national commercial management, global marketing and government. Karen is the former President (Asia Pacific and Middle East) of ResMed Inc (ASX: RMD) and prior to this held several senior roles with Johnson & Johnson Medical Devices, including Global Vice President (based in USA). Karen's most recent executive roles include CEO of Healthdirect and the inaugural Chief Executive of Jobs for NSW, with both roles fostering relationships across all tiers of government. Karen also holds several non-executive roles and is on the Board of Somnomed Ltd (ASX: SOM), The North Foundation and is the Interim Chair of the Australian Vaccine Research Alliance. She was also a NSW finalist for Telstra Businesswoman of the Year 2017.
|Professor Camile Farah||Non-Executive Director||May 2021||
Professor Farah is executive, academic, researcher and author with 25 years' experience in the healthcare, biotech and medical research sectors. He is dual trained physician and pathologist, with public and private appointments at Fiona Stanley Hospital, Hollywood Private Hospital, Qscan Radiology Clinics, Australian Clinical Labs, and Genomics for Life. Professor Farah is experienced in oral cancer and precancerous pathology based on his clinical and research experience having published 250 clinical and scientific articles and a bestselling textbook. He is a former Dean at the University of Western Australia, and currently an Adjunct Professor at CQ University and an Honorary Professorial Research Fellow at the Peter MacCallum Cancer Centre. In addition to managing his own consulting business, he is Executive Director of the Australian Centre for Oral Oncology Research & Education which undertakes cutting edge research in head and neck cancer. He currently serves as a non-executive director of the Australian and New Zealand Head and Neck Cancer Society.
|Mr Justin Mouchacca||Company Secretary||Dec 2016||
|Justin Mouchacca||Company Secretary||
|HSBC Custody Nominees (Australia) Limited||90,406,295||14.67%|
|Peters Investment Ply Ltd||71,000,000||11.52%|
|Ibsen Pty Ltd (Narula Family Set No.3 A/C)||37,100,000||6.02%|
|Citicorp Nominees Pty Limited||26,730,263||4.34%|
|BNP Paribas Noms Pty Ltd (Drp)||21,716,371||3.52%|
|Lightstorm Pty Ltd (Hotspice A/C)||15,460,000||2.51%|
|Harech Ply Ltd (Porter Super Fund A/C)||14,200,868||2.30%|
|Mr Chris Graham & Mrs Diane Graham (C & D Graham S/F A/C)||11,003,506||1.79%|
|LDL Nominees Pty Ltd (LL & DL Family A/C)||8,725,000||1.42%|
|Mr Alfred J Winklemeier & Mrs Christine E Winklemier||7,850,000||1.27%|
|Dr Philip J Currie & Mrs Anne J Currie (Currie Family Superfund A/C)||7,597,500||1.23%|
|Sash Pty Ltd (Knezevic Super Fund A/C)||6,837,964||1.11%|
|Dixson Trust Pty Limited||6,335,702||1.03%|
|Semblance Pty Ltd (Graeme Mutton Retire S/Fund)||6,300,000||1.02%|
|D &K Corps Retirement Pty Ltd (D & K Corps Family A/C)||6,161,112||1.00%|
|Kebin Nominees Pty Ltd||5,110,479||0.83%|
|Hensman Nominees Pty Ltd (Swedcan A/C)||4,850,000||0.79%|
|Ibsen Pty Ltd (Ibsen Superfund A/C)||4,300,000||0.70%|
|Mr Christopher J Martin||4,209,448||0.68%|
|Mr Wally Knezevic||4||0.67%|